Oxytocin
Also known as: Pitocin, Syntocinon
Overview
Oxytocin is a hypothalamic neuropeptide, a naturally occurring hormone produced in the brain. It is involved in a variety of physiological and psychological functions, primarily related to social bonding, reproduction, and childbirth. While often referred to as the "love hormone," its actions are far more complex and nuanced than this simple label suggests. Oxytocin is FDA-approved for specific medical uses, primarily related to labor induction and postpartum hemorrhage control.
The mechanism of action for oxytocin involves binding to oxytocin receptors, which are G-protein coupled receptors distributed throughout the brain and body. This binding triggers intracellular signaling cascades that influence a wide range of processes. In the context of childbirth, oxytocin stimulates uterine contractions, facilitating labor and delivery. Postpartum, it helps to contract the uterus to prevent excessive bleeding. In the brain, oxytocin modulates neuronal activity in regions associated with social behavior, anxiety, and stress.
The current research landscape surrounding oxytocin is extensive, with over 33,500 research papers published on the topic. ClinicalTrials.gov lists approximately 50 clinical trials involving oxytocin, exploring its potential applications in diverse areas. For instance, one completed study at the University Hospital in Strasbourg, France, with a sample size of 300, investigated predictors of failure of sulprostone treatment in postpartum hemorrhage, a condition where oxytocin is often a first-line treatment. Another completed study at the University of Alabama at Birmingham, involving 281 participants, examined racial and socioeconomic disparities in chronic low back pain, potentially exploring oxytocin's role in pain modulation. A study at Universitaire Ziekenhuizen KU Leuven, currently active but not recruiting, is investigating the effect of perinatal stress on the development of preterm infants, suggesting an interest in oxytocin's influence on early development. Research papers highlight diverse areas of interest, ranging from synaptic plasticity in autism models ("Knockdown of Ddx3x in mPFC induces autistic-like phenotype in mice via altered synaptic plasticity") to the relationship between amenorrhea and eating disorders ("Longer duration of amenorrhea is associated with lower delay discounting and less hedonic eating in girls and young women with low-weight eating disorders").
Regarding safety, the FDA adverse event reporting system has recorded 2904 reports associated with oxytocin. Notably, none of these reports were classified as serious. The most common reported reactions include foetal and maternal exposure during pregnancy, instances where the drug was deemed ineffective, exposure during pregnancy, and premature birth. It is important to note that these reports do not necessarily establish a causal link between oxytocin and the reported events, but rather represent potential associations identified through post-market surveillance.
Oxytocin's regulatory status is currently unregulated, meaning it is not subject to the same level of control as prescription drugs or controlled substances, outside of its approved medical uses. It is not classified as a Category 2 substance, meaning it is not banned from compounding pharmacies.
Typically, oxytocin is used in medical settings by healthcare professionals for labor induction and postpartum hemorrhage management. Outside of these approved uses, individuals may explore oxytocin for its potential effects on sexual health, cognitive function, and immune support, although the scientific evidence supporting these uses is often preliminary or inconclusive. Given its unregulated status, access to oxytocin for non-medical purposes may vary, and the quality and purity of products obtained from unregulated sources can be uncertain.
The ongoing research efforts and the relative lack of serious adverse event reports suggest a continued interest in exploring the therapeutic potential of oxytocin, while the unregulated status outside of approved medical uses highlights the need for caution and informed decision-making.
Evidence Breakdown
21 studies analyzedResearch Timeline
Research spans 2025β2026
Score Profile
193 Clinical Trials
- [Boosting oxytocin in postpartum depression]. Published COMPLETED Ned Tijdschr Geneeskd
- Nalbuphine as a Bridge to Delayed Epidural Analgesia: A Randomized Trial on First-Stage Labor Duration. Published COMPLETED Drug Des Devel Ther
- Auricular magnetic bead acupressure improves postpartum sleep quality and fatigue, and reduces epidural-related maternal fever in primiparas: a randomized controlled trial. Published COMPLETED Front Med (Lausanne)
- The role of the oxytocinergic system in oral microbiome composition in children with autism: evidence from a randomized controlled trial of intranasal oxytocin. Published COMPLETED Transl Psychiatry
- Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner. Published COMPLETED Psychol Med
Showing 5 of 193 trials.
20 Research Papers
- Knockdown of Ddx3x in mPFC induces autistic-like phenotype in mice via altered synaptic plasticity. Transl Psychiatry unknown 89 citations
- Longer duration of amenorrhea is associated with lower delay discounting and less hedonic eating in girls and young women with low-weight eating disorders. Sci Rep unknown 70 citations
- Unraveling the Dynamics of Oxytocin inΒ Hypothalamic Neurons. Traffic unknown 67 citations
- Postpartum Depression and the Emerging Mother-Infant Relationship: Associations With Selective Serotonin Reuptake Inhibitor Medication Use. JAACAP Open unknown 50 citations
- Effect of labor dance on induction duration, first-stage labor, and maternal anxiety in pregnant women with term premature rupture of membranes: A randomized controlled trial. Eur J Midwifery unknown 33 citations
Showing 5 of 20 papers by citation count.
FDA Data
Not FDA-Approved
Oxytocin has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Use Cases
Clinics Offering Oxytocin
All clinics →Peptide therapy clinics in the CheckPeptides US directory that reference Oxytocin or overlap with its common use cases. Sorted by Google review volume and rating.
- Next Health in West HollywoodLos Angeles, CA matching use-case5.0β2,219 reviews
- Soak & Sage - A Social Wellness SpaSeattle, WA matching use-case4.9β1,951 reviews
- Nulevel WellnessPhoenix, AZ matching use-case5.0β1,726 reviews
- Nulevel WellnessMesa, AZ matching use-case5.0β1,726 reviews
- Haus of ConfidencePhoenix, AZ matching use-case4.9β1,669 reviews
- Next Health Studio CityLos Angeles, CA matching use-case5.0β1,439 reviews
- Innovative Lasers of Houston Specializing in Weight LossHouston, TX matching use-case4.6β1,399 reviews
- Dr. Randolph's Ageless & Wellness CenterJacksonville, FL matching use-case4.9β1,215 reviews
Frequently Asked Questions
How does Oxytocin supposedly enhance sexual health and cognitive function, given it's a hypothalamic neuropeptide?
What specific safety concerns should researchers be aware of when studying Oxytocin, considering the FDA adverse event reports?
Is Oxytocin legally available for research purposes, and are there any restrictions on its use given its FDA approval status?
Are there any established peptide alternatives to Oxytocin for immune support, and how does Oxytocin compare in terms of efficacy and safety?
With over 33,500 research papers published, what are the key areas where further Oxytocin research is most needed to improve its trust score?
Related Peptides
KPV
Alpha-MSH fragment
LL-37
Host defence / antimicrobial peptide
Glutathione
Antioxidant tripeptide
Gonadorelin
GnRH analogue
Selank
Anxiolytic nootropic peptide
Bremelanotide
Melanocortin receptor agonist
Quick Facts
- Classification
- Hypothalamic neuropeptide
- Molecular Weight
- 1007.2 Da
- PubChem
- CID 439302 ↗
- Regulatory Status
- N/A
Score Breakdown
- Evidence Quality (30%)
- 50
- Safety Profile (25%)
- 85
- Study Design (20%)
- 43
- Research Depth (15%)
- 90
- Research Recency (10%)
- 100
Evidence Summary
- Clinical Trials
- 193
- Research Papers
- 20
- Trust Score
- 68.3/100
- Grade
- B-